TrialJournal of the National Cancer Institute2017
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.
Carlos Bais et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
64 papers cite itlatest 60 shown
this paperpooled ittrialcites it